ClinicalTrials.gg
CompletedNCT01947855Updated Dec 24, 2014Results posted

Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Placebo and Empagliflozin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 2 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2014-12-24.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
78th of 130
60 · median 79
Started
2013
with 3 others
Phase 3
28 of 130
1 open now
Registered
31st of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 78th largest by enrollment, is one of 4 that started in 2013, is one of 28 in phase 3, and was the 31st registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To evaluate the efficacy of empagliflozin administered orally once daily in postprandial glucose and 24-hour glycaemic variability compared to placebo given for 4 weeks as mono-therapy in Japanese patients with type 2 diabetes mellitus with insufficient glycaemic control on no antidiabetic treatment.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes mellitus prior to
  • Male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are:

    • drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,
    • pre-treated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as pre-treatment drug only if the dose is equal or less than a half of daily maximum approval dose.)
  • Glycosylated () at Visit 1 (screening)

    • for patients without antidiabetic therapy : HbA1c >=7.0 to =\<10.0%
    • for patients with one oral antidiabetic drug : HbA1c >=7.0 to =\<9.5%

Exclusion criteria

Exclusion criteria:

  • Uncontrolled hyperglycaemia with a glucose level >240 mg/dL (>13.3 mmol/L)
  • Impaired renal function, defined as estimated (eGFR) \<60 mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (MDRD) formula)
  • Acute coronary syndrome, stroke or (TIA) within 12 weeks prior to
  • Indication of liver disease, defined by serum levels of either (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x (ULN)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Empagliflozin low dose

    Empagliflozin low dose tablet once daily

    Drug: Empagliflozin · Drug: Placebo

  • Experimental
    Empagliflozin high dose

    Empagliflozin high dose tablet once daily

    Drug: Placebo · Drug: Empagliflozin

  • Placebo comparator
    Placebo

    Placebo tablet once daily

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo tablet matching Empagliflozin low dose

  • Empagliflozin low dose

  • DrugPlacebo

    Placebo tablet matching Empagliflozin high dose

  • DrugPlacebo

    Placebo tablet matching Empagliflozin low dose

  • Empagliflozin high dose tablet once daily

  • DrugPlacebo

    Placebo tablet matching Empagliflozin high dose

06

What researchers measure

Primary outcomes

  1. Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment

    The primary endpoint is the change in AUC1-4h for postprandial plasma glucose based on meal tolerance test from baseline after 28 days of treatment. Baseline refers to the last observation prior to administration of randomised study medication.

    Time frame: 1h, 1.5h, 2h, 2.5, 3h, 3.5h and 4h after drug administration at day -1 (baseline), and 1h, 1.5h, 2h, 2.5, 3h, 3.5h and 4h after drug administration at day 28

07

Results

Posted Dec 24, 2014

Participant flow

Participant flow — Overall Study
MilestonePlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Started212019
Completed202019
Not completed100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryChange in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment

The primary endpoint is the change in AUC1-4h for postprandial plasma glucose based on meal tolerance test from baseline after 28 days of treatment. Baseline refers to the last observation prior to administration of randomised study medication.

Time frame:
1h, 1.5h, 2h, 2.5, 3h, 3.5h and 4h after drug administration at day -1 (baseline), and 1h, 1.5h, 2h, 2.5, 3h, 3.5h and 4h after drug administration at day 28
Reported as:
Least squares mean · mg*h/dL
Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment
mg*h/dLPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment-18.07 ± 13.89-103.56 ± 14.24-122.94 ± 14.35
Statistical analysis
  • Placebo vs Empagliflozin 25 mg · ANCOVA · p = <0.0001 · Mean difference (net): -104.87 · 95% CI -144.77 to -64.97Model includes treatment, number of previous antidiabetic medication, baseline renal function, baseline HbA1c and baseline AUC1-4h for plasma glucose.
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = <0.0001 · Mean difference (net): -85.49 · 95% CI -126.01 to -44.97Model includes treatment, number of previous antidiabetic medication, baseline renal function, baseline HbA1c and baseline AUC1-4h for plasma glucose.

Adverse events

Collected over between the first drug intake of study medication and 7 days after last drug intake of study medication, up to 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/21 (0%)1/21 (4.8%)
Empagliflozin 10 mg—0/20 (0%)2/20 (10%)
Empagliflozin 25 mg—0/19 (0%)3/19 (15.8%)
Most frequent other events
Most frequent other events
EventPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
NasopharyngitisInfections and infestations1/212/200/19
Anal inflammationGastrointestinal disorders0/210/201/19
Rash pruriticSkin and subcutaneous tissue disorders0/210/201/19
PollakiuriaRenal and urinary disorders0/210/201/19
BartholinitisReproductive system and breast disorders0/210/201/19

Baseline characteristics

Full analysis set: all patients treated with at least 1 dose of randomised study drug, and with a baseline AUC1-4h for plasma glucose.

Age, Continuous
Age, Continuous(years)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Mean60.7 ± 10.864.8 ± 5.962.6 ± 7.862.7 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Female46313
Male17141647
08

Study locations

2 sites
  • 1245.35.002 Boehringer Ingelheim Investigational Site
    Shinjyuku-ku, Tokyo, Japan
  • 1245.35.001 Boehringer Ingelheim Investigational Site
    Suita-shi, Osaka, Japan
09

References and documents

Publications

  • Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034. PubMed 35472672 ↗
  • Nishimura R, Tanaka Y, Koiwai K, Ishida K, Salsali A, Kaspers S, Kohler S, Lund SS. Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Adv Ther. 2019 Oct;36(10):2769-2782. doi: 10.1007/s12325-019-01045-x. Epub 2019 Aug 23. PubMed 31444706 ↗
  • Nishimura R, Tanaka Y, Koiwai K, Inoue K, Hach T, Salsali A, Lund SS, Broedl UC. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015 Jan 30;14:11. doi: 10.1186/s12933-014-0169-9. PubMed 25633683 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2013
First posted
Sep 23, 2013
Start
Sep 2013
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Dec 24, 2014
Last update
Dec 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01947855
Responsible party
Sponsor
First posted
Sep 23, 2013
Start date
Sep 2013
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Dec 24, 2014
Last update
Dec 24, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion